Modified Docetaxel and Cisplatin in Combination with Capecitabine (DCX) as a First-Line Treatment in HER2-Negative Advanced Gastric Cancer |
Bilici, Ahmet
(Department of Medical Oncology, Medical Faculty, Istanbul Medipol University)
Selcukbiricik, Fatih (Department of Medical Oncology, Sisli Etfal Education and Research Hospital) Demir, Nazan (Department of Medical Oncology, Sisli Etfal Education and Research Hospital) Ustaalioglu, Bala Basak Oven (Department of Medical Oncology, Haydarpasa Numune Education and Research Hospital) Dikilitas, Mustafa (Department of Medical Oncology, Acibadem Maslak Hospital) Yildiz, Ozcan (Department of Medical Oncology, Medical Faculty, Istanbul Medipol University) |
1 | Kang YK, Kang WK, Shin DB, et al (2009). Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol, 20, 666-73. DOI ScienceOn |
2 | Glimelius B, Ekstrom K, Hoffman K, et al (1997). Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol, 8, 163-8. DOI ScienceOn |
3 | Hong YS, Song SY, Lee SI, et al (2004). A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. Ann Oncol, 15, 1344-7. DOI ScienceOn |
4 | Kang YK, Ryu MH, Yoo C, et al (2011). Phase I/II study of a combination of docetaxel, capecitabine, and cisplatin (DXP) as first-line chemotherapy in patients with advanced gastric cancer. Cancer Chemother Pharmacol, 67, 1435-43. DOI |
5 | Kim NK, Park YS, Heo DS, et al (1993). A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer, 71, 3813-8. DOI ScienceOn |
6 | Koizumi W, Saigenji K, Ujiie S, et al (2003). A pilot phase II study of capecitabine in advanced or recurrent gastric cancer. Oncology, 64, 232-6. DOI |
7 | Kos FT, Uncu D, Ozdemir N, et al (2011). Comparison of cisplatin-5-fluorouracil-folinic acid versus modified docetaxel-cisplatin-5-fluorouracil regimens in the first-line treatment of metastatic gastric cancer. Chemotherapy, 57, 230-5. DOI |
8 | Lorenzen S, Hentrich M, Haberl C, et al (2007). Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial. Ann Oncol, 18, 1673-9. DOI |
9 | Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M (1995). Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer, 71, 587-91. DOI ScienceOn |
10 | Okines AF, Norman AR, McCloud P, Kang YK, Cunningham D (2009). Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol, 20, 1529-34. DOI ScienceOn |
11 | Ozdemir NY, Abali H, Oksuzoglu B, et al (2010). The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma. Med Oncol, 27, 680-4. DOI ScienceOn |
12 | Polyzos A, Felekouras E, Karatzas T, et al (2012). Modified docetaxel-cisplatin in combination with capecitabine as first-line treatment in metastatic gastric cancer. a phase II study. Anticancer Res, 32, 4151-6. |
13 | Siegel R, Naishadham D, Jemal A (2013). Cancer statistics, 2013. CA Cancer J Clin, 63, 11-30. DOI ScienceOn |
14 | Sym SJ, Chang HM, Ryu MH, et al (2010). Neoadjuvant docetaxel, capecitabine and cisplatin (DXP) in patients with unresectable locally advanced or metastatic gastric cancer. Ann Surg Oncol, 17, 1024-32. DOI |
15 | Thuss-Patience PC, Hofheinz RD, Arnold D, et al (2012). Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Ann Oncol, 23, 2827-34. DOI |
16 | Wagner AD, Unverzagt S, Grothe W, et al (2010). Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev, 3, 4064. |
17 | Yoney A, Isikli L (2013). Can capecitabine be used instead of concurrent bolus 5-FU in postoperative chemoradiotherapy for gastric adenocarcinoma? Asian Pac J Cancer Prev, 14, 5127-31. 과학기술학회마을 DOI ScienceOn |
18 | Wagner AD, Grothe W, Haerting J, et al (2006). Chemotherapy in advanced gastric cancer: a systematic review and metaanalysis based on aggregate data. J Clin Oncol, 24, 2903-9. DOI ScienceOn |
19 | Van Cutsem E, Moiseyenko VM, Tjulandin S, et al (2006). Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol, 24, 4991-7. DOI ScienceOn |
20 | Vanhoefer U, Rougier P, Wilke H, et al (2000). Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol, 18, 2648-57. |
21 | Crew KD, Neugut AI (2006). Epidemiology of gastric cancer. World J Gastroenterol, 12, 354-62. |
22 | Cunningham D, Starling N, Rao S, et al (2008). Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med, 358, 36-46. DOI ScienceOn |
23 | Alici S, Buyukberber S, Alkis N, et al Anatolian Society of Medical Oncology (2013). Low-dose docetaxel/cisplatinleucovorin and 46 hour infusional fluorouracil in metastatic gastric carcinoma. Asian Pac J Cancer Prev, 14, 423-7. 과학기술학회마을 DOI |
24 | Bang YJ, Van Cutsem E, Feyereislova A, et al (2010). Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet, 376, 687-97. DOI ScienceOn |
25 | Eisenhauer EA, Therasse P, Bogaerts J, et al (2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 45, 228-47. DOI ScienceOn |
26 | Field K, Michael M, Leong T (2008). Locally advanced and metastatic gastric cancer: current management and new treatment developments. Drugs, 68, 299-317. DOI |